CD274 and neoplasm: By expressing a multitude of putative, uncharacterized, tumor antigens within VSV, for the first time, a combination of VSV and anti-PD-L1 ICI generated significantly improved therapy over anti-PD-L1 ICI treatment alone with 100% of mice surviving to day 150 (Fig. 7C).